Patient Response and Adverse Reaction Prediction

HuProt for Treatment Strategies and Adverse Reaction Prediction

Predict both treatment response and immune-related adverse events

Autoantibodies can play a role in predicting patient response to treatment. Combining multiple autoantibodies into biomarker panels or signatures can predict both treatment response and immune-related adverse events (irAEs). Integrating autoantibody data with other clinical and molecular markers can enhance risk prediction models and facilitate personalized treatment approaches.

In the featured publication below, HuProt™ microarray was used to identify autoantibody signatures that have the potential to predict both disease recurrence and immune-related adverse events in melanoma patients treated with checkpoint inhibitor adjuvant immunotherapy.